A Trial of Regorafenib Plus Lorigerlimab in Patients With Locally Recurrent or Regrowing pMMR/MSS Localized Rectal Cancer

NCT07223567 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped 0 participants enrolled

Conditions

Rectal Cancer
Rectal Cancer Recurrent

Interventions

DRUG: Regorafenib
DRUG: Lorigerlimab

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]
[object Object]